Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Cell Therapy in Hematological Malignancies - A Systematic Review and Meta Analysis - PubMed
3 hours ago
- #hematological malignancies
- #CAR-T cell therapy
- #meta-analysis
- CAR T therapy involves genetically modifying autologous T cells to target tumor cells in hematological malignancies.
- This meta-analysis evaluated efficacy and safety, including response rates, survival outcomes, and treatment-related adverse events.
- The study followed PRISMA guidelines and analyzed 428 records from 2019 to 2024 across multiple databases.
- Twelve studies were included, showing high overall response rate (ORR) and complete response (CR) in B-cell malignancies.
- ORR reached 90.5% in relapsed/refractory B-cell non-Hodgkin lymphoma and 81% remission in B-cell acute lymphoblastic leukemia.
- Cytokine release syndrome (CRS) was common but mostly mild to moderate; neurotoxicity and graft-versus-host disease were less frequent.
- Substantial heterogeneity was observed for ORR, CR, and CRS outcomes across studies.
- Most studies were of good quality, though moderate bias related to missing data and design differences was noted.
- CAR T therapy demonstrates high response rates and durable remission, particularly in B-cell malignancies compared to myeloid ones.
- The findings emphasize the need for protocol optimization, patient selection, and toxicity management to improve outcomes.
- Conclusion: CAR T therapy is effective for relapsed/refractory hematological malignancies with controllable toxicity, but durability and access need improvement.